Extens has made an investment in Discngine

Back Published on 08/12/2017

Discngine, a software company specialising in applications for life sciences research, today announced a Series A financing round of €1.1 million ($1.3M), received from Extens. The funds raised will allow Discngine to move forward with its Software-as-a-Service (SaaS) solution offering for the life science industry.

Based in Paris, Discngine already offers software for data management, visualisation and decision-making processes in the life sciences industry, with leading pharmaceutical and cosmetics firms among it clients.

« We are excited to invest in Discngine. The company has developed a state-of-the-art technology platform that increases the efficiency of drug discovery, helping to find ‘bankable’ molecules. The challenge is not only financial, but above all medical. This is a good example of our strategy: identifying French e-health SMEs that develop promising technologies, helping them accelerate their development and contributing to an improvement in our health system. »

Arnaud HOUETTE